Synaptogenix Cash on Hand 2020-2025 | TAOX
Synaptogenix cash on hand from 2020 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Synaptogenix Annual Cash on Hand
(Millions of US $) |
| 2024 |
$18 |
| 2023 |
$30 |
| 2022 |
$37 |
| 2021 |
$34 |
| 2020 |
$6 |
| 2019 |
$17 |
Synaptogenix Quarterly Cash on Hand
(Millions of US $) |
| 2025-03-31 |
$15 |
| 2024-12-31 |
$18 |
| 2024-09-30 |
$22 |
| 2024-06-30 |
$27 |
| 2024-03-31 |
$28 |
| 2023-12-31 |
$30 |
| 2023-09-30 |
$32 |
| 2023-06-30 |
$33 |
| 2023-03-31 |
$36 |
| 2022-12-31 |
$37 |
| 2022-09-30 |
$26 |
| 2022-06-30 |
$29 |
| 2022-03-31 |
$31 |
| 2021-12-31 |
$34 |
| 2021-09-30 |
$31 |
| 2021-06-30 |
$32 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2019-12-31 |
$17 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.012B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
